Friedreich ataxia is the most common inherited ataxia, with a wide phenotypic spectrum. It is generally caused by GAA expansions on both alleles of FXN, but a small percentage of patients are compound heterozygotes for a pathogenic expansion and a point mutation. Two recent diagnostic innovations are further characterizing individuals with the phenotype but without the classic genotypes. First, lateral-flow immunoassay is able to quantify the frataxin protein, thereby further characterizing these atypical individuals as likely affected or not affected, and providing some correlation to phenotype. It also holds promise as a biomarker for clinical trials in which the investigative agent increases frataxin. Second, gene dosage analysis and the identification of affected individuals with gene deletions introduce a novel genetic mechanism of disease. Both tests are now clinically available and suggest a new diagnostic paradigm for the disorder. Genetic counseling issues and future diagnostic testing approaches are considered as well.
GeoffreyGBarbeauABretonG. Clinical description and roentgenologic evaluation of patients with Friedreich’s ataxia. Can J Neurol Sci. 1976;3:279–286.
5.
HardingAE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104:589–620.
6.
CampuzanoVMonterminiLMoltoMD. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–1427.
7.
DürrACosseeMAgidY. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335:1169–1175.
8.
McCabeDJRyanFMooreDP. Typical Friedreich’s ataxia without GAA expansions and GAA expansion without typical Friedreich’s ataxia. J Neurol. 2000;247(5):346–355.
9.
SchölsLAmoiridisGPrzuntekH. Friedreich’s ataxia. Revision of the phenotype according to molecular genetics. Brain. 1997;120(pt 12):2131–2140.
10.
FillaADe MicheleGCoppolaG. Accuracy of clinical diagnostic criteria for Friedreich’s ataxia. Mov Disord. 2000;15(6):1255–1258.
11.
MonterminiLRichterAMorganK. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol. 1997;41:675–682.
12.
BhidayasiriRPerlmanSPulstSMGeschwindDH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch Neurol. 2005;62:1865–1869.
13.
De CastroMGarcia-PlanellsJMonrosE. Genotype and phenotype analysis of Friedreich’s ataxia compound heterozygous patients. Hum Genet. 2000;106:86–92.
14.
CosseeMDurrASchmittM. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999;45:200–206.
15.
ForrestSMKnightMDelatyckiMB. The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics. 1998;1:253–257.
16.
WillisJHIsayaGGakhO. Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers. Mol Genet Metab. 2008;94:491–497.
17.
DeutschECSantaniABPerlmanSL. A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010;101:238–425.
18.
SaccàFPuorroGAntenoraA. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS One. 2011;6(3):1–9.
19.
BoeschSSturmBHeringS. Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007;62:521–524.
20.
NachbauerWWanschitzJSteinkellnerH. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov Disord. 2011;26(10):1935–1938.
21.
ZühlkeCHDalskiAHabeckM. Extension of the mutation spectrum in Friedreich’s ataxia: detection of an exon deletion and novel missense mutations. Eur J Hum Genet. 2004;12:979–982.
22.
CampuzanoVMonterminiLLutzY. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet. 1997;6(11):1771–1780.
23.
SteinkellnerHScheiber-Mojdehkar GoldenbergHSturmB. A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Analytica Chimica Acta. 2010;659:129–132.
24.
PercyMEAndrewsDFThompsonMW. Serum creatine kinase in the detection of Duchenne muscular dystrophy carriers: effects of season and multiple testing. Muscle Nerve. 1982;5:58–64.
KlopstockTChahrokh-ZahedSHolinski-FederE. Markedly different course of Firedreich’s ataxia in sib pairs with similar GAA repeat expansions in the frataxin gene. Acta Neropathol. 1999;97:139–142.
29.
MajewskiJSchwartzentruberJLalondeE. What can exome sequencing do for you?J Med Genet. 2011;48:580–589.
30.
BamshadMJNgSBBighamAW. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev. 2011;12:745–755.
31.
TeerJKMullikinJC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet. 2010;19(R2):R145–R151.
